(tel a VAN sin)
- Telavancin Hydrochloride
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Reconstituted, Intravenous [preservative free]:
Vibativ: 250 mg (1 ea); 750 mg (1 ea)
Brand Names: U.S.
Exerts concentration-dependent bactericidal activity; inhibits bacterial cell wall synthesis by blocking polymerization and cross-linking of peptidoglycan by binding to D-Ala-D-Ala portion of cell wall. Unlike vancomycin, additional mechanism involves disruption of membrane potential and changes cell permeability due to presence of lipophilic side chain moiety.
Vss: 0.13 L/kg
Urine (~76%); feces (<1%)
~90%; primarily to albumin
Special Populations: Renal Function Impairment
The mean AUC values were approximately 13%, 29%, and 118% higher for subjects with CrCl >50-80 mL/minute, CrCl 30-50 mL/minute, and CrCl ≤30 mL/minute, respectively when compared with subjects with healthy renal function.
Use: Labeled Indications
Complicated skin and skin structure infections: Treatment of complicated skin and skin structure infections caused by susceptible gram-positive organisms including methicillin-susceptible or -resistant Staphylococcus aureus, vancomycin-susceptible Enterococcus faecalis, and Streptococcus pyogenes, Streptococcus agalactiae, or Streptococcus anginosus group
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP): Treatment of HABP/VABP caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not appropriate
Hypersensitivity to telavancin or any component of the formulation; concomitant use of intravenous unfractionated heparin
Complicated skin and skin structure infection: Adults: IV: 10 mg/kg every 24 hours for 1-2 weeks
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP): Adults: IV: 10 mg/kg every 24 hours for 1-3 weeks
Dosage adjustment in renal impairment: Note: Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.
CrCl >50 mL/minute: No dosage adjustment necessary
CrCl 30-50 mL/minute: 7.5 mg/kg every 24 hours
CrCl 10 to <30 mL/minute: 10 mg/kg every 48 hours
CrCl <10 mL/minute: No dosage adjustment provided in manufacturer’s labeling (has not been studied).
ESRD and hemodialysis patients: No dosage adjustment provided in manufacturer’s labeling (has not been studied).
Dosage adjustment in hepatic impairment:
Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.
Severe hepatic impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer's labeling (has not been studied).
Hazardous agent; use appropriate precautions for handling and disposal (NIOSH 2014 [group 3]).
Reconstitute 250 mg vial with 15 mL of D5W, NS, or SWFI to yield 15 mg/mL (total volume of ~17 mL). Reconstitute 750 mg vial with 45 mL of of D5W, NS, or SWFI to yield 15 mg/mL (total volume of ~50 mL). Allow vacuum to pull the diluent into the vial; discard vial if this did not occur. Reconstitution generally takes <2 minutes, although may take up to 20 minutes. Do not shake the vial or final solution for infusion. Prior to administration, dilute dose in 100-250 mL D5W, LR, or NS to a final concentration of 0.6-8 mg/mL.
Administer IV over 60 minutes. Other medications should not be infused simultaneously through the same IV line. When the same intravenous line is used for sequential infusion of other medications, flush line with D5W, LR, or NS before and after infusing telavancin.
Red-man syndrome may occur if the infusion is too rapid. It is not an allergic reaction, but may be characterized by hypotension and/or a maculopapular rash appearing on the face, neck, trunk, and/or upper extremities. If this should occur, discontinuing or slowing the infusion rate may eliminate these reactions.
Hazardous agent; use appropriate precautions for handling and disposal (NIOSH 2014 [group 3]).
Stable in NS, LR, D5W.
Store intact vials at 2°C to 8°C (35°F to 46°F); excursions permitted up to 25°C (77°F); avoid excess heat. Note: Vials contain no bacteriostatic agent. Reconstituted solution in the vial should be used within 12 hours at room temperature or 7 days refrigerated; solutions admixed for infusion are stable at room temperature for 12 hours or under refrigeration for 7 days. Total time in vial plus time in infusion bag should not exceed 12 hours at room temperature or 7 days if refrigerated at 2°C to 8°C (35°F to 46°F). Solutions admixed for infusion can also be stored at -30°C to -10°C (-22°F to 14°F) for ≤32 days.
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Heparin: Telavancin may diminish the therapeutic effect of Heparin. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses. Avoid combination
Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Avoid combination
Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents. Avoid combination
Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents. Avoid combination
Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible. Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm. Consider therapy modification
QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents. Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification
Interferes with the following coagulation assessments when using samples drawn 18 hours or less after telavancin administration (causes artificially increased clotting times): PT, INR, aPTT, ACT, Xa (coagulation based assay). Collect blood samples for these coagulation tests as close as possible prior to administration of the next dose of telavancin, use a non-phospholipid dependent coagulation test (eg, bleeding time, factor Xa [chromogenic assay], platelet aggregation study, thrombin time), or select an alternative anticoagulant not requiring aPTT monitoring; concomitant use of telavancin and IV unfractionated heparin is contraindicated.
Interferes with urine protein via qualitative dipstick and quantitative dye methods.
Central nervous system: Insomnia (13%), psychiatric disturbance (12%), headache (11%)
Gastrointestinal: Metallic taste (33%), nausea (5% to 27%), vomiting (5% to 14%)
Genitourinary: Proteinuria (13%)
Renal: Increased serum creatinine (8% to 16%)
1% to 10%:
Central nervous system: Dizziness (6%), paresthesia (5%), local pain (4%), rigors (4%)
Dermatologic: Pruritus (3% to 6%), skin rash (4%), localized erythema (3%)
Endocrine & metabolic: Albuminuria (micro) (7%), hypokalemia (7%)
Gastrointestinal: Diarrhea (7%), decreased appetite (3%), abdominal pain (2%)
Genitourinary: Acute renal failure (5%)
Hematologic & oncologic: Thrombocytopenia (7%)
Renal: Renal insufficiency (3%)
Respiratory: Dyspnea (8%)
<1% (Limited to important or life-threatening): Clostridium difficile associated diarrhea, hearing loss (transient), hypersensitivity reaction, nephrotoxicity, prolonged Q-T interval on ECG, urticaria
Concerns related to adverse effects:
• Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported after first or subsequent doses; some have been fatal. Discontinue if hypersensitivity or rash occurs. Telavancin is a semisynthetic derivative of vancomycin; cross-reactivity rates are unknown. Use with caution in patients with known vancomycin hypersensitivity.
• Cardiac conduction alteration: May prolong QTc interval; avoid use in patients with congenital long QT syndrome, known QTc prolongation, uncompensated heart failure, or severe left ventricular hypertrophy (were excluded from studies); use with caution in patients with concurrent administration of other medications known to prolong the QT interval. Clinical studies indicate mean maximal QTc prolongation of 12 to 15 msec at the end of 10 mg/kg infusion.
• Infusion reactions: Rapid IV administration may result in flushing, rash, urticaria, and/or pruritus; slowing or stopping the infusion may alleviate these symptoms.
• Nephrotoxicity: [U.S. Boxed Warning]: New onset or worsening renal impairment has occurred. Monitor renal function prior to, during (at least every 48 to 72 hours; more frequently if indicated), and following therapy in all patients. Usual risk factors include concomitant nephrotoxic medications or baseline comorbidities associated with decreased renal function (eg baseline renal dysfunction, diabetes, hypertension, or heart failure). Contains solubilizer cyclodextrin (hydroxypropyl-beta-cyclodextrin) which may accumulate in patients with renal dysfunction, although the clinical significance of this finding is uncertain (Luke, 2010).
• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.
• Renal impairment: [U.S. Boxed Warning]: In clinical studies, patients with pre-existing moderate-to-severe renal impairment (CrCl ≤50 mL/minute) treated for hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) had increased (all cause) mortality versus vancomycin. Use in HABP/VABP only when benefit outweighs risk. In patients with complicated skin and skin structure infections, efficacy may be reduced in patients with a baseline CrCl ≤50 mL/minute.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Elderly: Lower doses are often required secondary to age-related decreases in renal function.
• Pregnancy: [U.S. Boxed Warning]: Based on animal data, adverse developmental outcomes have been observed. Prior to use, women of childbearing potential should have a serum pregnancy test. Use of telavancin is not recommended during pregnancy unless the potential benefit outweighs the risk to the fetus.
• Hazardous agent: Use appropriate precautions for handling and disposal (NIOSH 2014 [group 3]).
• Coagulation tests: May interfere with tests used to monitor coagulation (eg, prothrombin time, INR, activated partial thromboplastin time, activated clotting time, coagulation based factor Xa tests) when samples drawn ≤18 hours after drug administration. Blood samples should be collected as close to the next dose of telavancin as possible or a non-phospholipid dependent coagulation test (eg, bleeding time, factor Xa [chromogenic assay], platelet aggregation study, thrombin time) should be used. Consider selecting an alternative anticoagulant not requiring aPTT monitoring; concomitant use of telavancin with IV unfractionated heparin is contraindicated.
Renal function (prior to start, every 48-72 hours; more frequently if indicated, and following therapy), pregnancy test
Pregnancy Risk Factor
[U.S. Boxed Warning]: Based on animal data, adverse developmental outcomes have been observed. Prior to use, women of childbearing potential should have a serum pregnancy test. Use of telavancin is not recommended during pregnancy unless the potential benefit to the mother outweighs the possible risk to the fetus. Telavancin crosses the placenta (Nanovskaya, 2012). In women of childbearing potential, effective contraception should be used during therapy.
Healthcare providers are encouraged to enroll women exposed to telavancin during pregnancy in the Vibativ Pregnancy Registry 855-633-8479).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience proteinuria, dysgeusia, nausea, headache, or diarrhea. Have patient report immediately to prescriber signs of renal impairment, tachycardia, arrhythmia, severe dizziness, syncope, flushing, rash during infusion, considerable injection site irritation, signs of pseudomembranous colitis (rare) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
More about telavancin
- Other brands: Vibativ